HIV therapy after treatment interruption in patients with multiple failure and more than 200 CD4+ T lymphocyte count

Journal of Medical Virology

Volumn 74, Issue 1, 2004, Pages 8-15

  Jaafar, Acil ^a   Massip, Patrice ^a   Sandres Sauné, Karine ^a   Souyris, Corinne ^a   Pasquier, Christophe ^a   Aquilina, Christian ^b   Izopet, Jacques ^a  

^a CHU PURPAN   (France)

^b Serv Univ Psychiat l'Enfant l'A   (France)

Author keywords

Antiretroviral therapy; HIV drug resistance; Resistance genotype shift; Salvage therapy; Treatment interruption

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CD4 ANTIGEN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADULT; AGED; ARTICLE; DRUG SAFETY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PERIPHERAL NEUROPATHY; RETREATMENT; SIDE EFFECT; STRUCTURAL GENE; THRUSH; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; VAGINA CANDIDIASIS; VIRUS LOAD;

ADULT; AGED; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CANDIDIASIS; CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HIV; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PERIPHERAL NERVOUS SYSTEM DISEASES; PROSPECTIVE STUDIES; RNA, VIRAL; SALVAGE THERAPY; VIREMIA;

EID: 3342943327     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmv.20139     Document Type: Article

References (31)

1. Albrecht D, Zollner B, Feucht HH, Lorenzen T, Laufs R, Stoehr A, Plettenberg A. 2002. Reappearance of HIV multidrug-resistance in plasma and circulating lymphocytes after reintroduction of antiretroviral therapy. J Clin Virol 24:93-98.
2. Baxter JD, Mayers DL, Wentworth DN, Neaton JD, Hoover ML, Winters MA, Mannheimer SB, Thompson MA, Abrams DI, Brizz BJ, Ioannidis JP, Merigan TC. 2000. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. Aids 14:F83-F93.
3. British HIV Association (BHIVA). 2001. Guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med 2:276-313.
4. Cingolani A, Antinori A, Rizzo MG, Murri R, Ammassari A, Baldini F, Di Giambenedetto S, Cauda R, De Luca A. 2002. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: A randomized study (ARGENTA). Aids 16:369-379.
5. Deeks SG, Wrin T, Liegler T, Hoh R, Hayden M, Barbour JD, Hellmann NS, Petropoulos CJ, McCune JM, Hellerstein MK, Grant RM. 2001. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med 344:472-480.
6. Deeks SG, Grant RM, Wrin T, Paxinos EE, Liegler T, Hoh R, Martin JN, Petropoulos CJ. 2003. Persistence of drug-resistant HIV-1 after a structured treatment interruption and its impact on treatment response. Aids 17:361-370.
7. Delaugerre C, Valantin MA, Mouroux M, Bonmarchand M, Carcelain G, Duvivier C, Tubiana R, Simon A, Bricaire F, Agut H, Autran B, Katlama C, Calvez V. 2001. Re-occurrence of HIV-1 drug mutations after treatment re-initiation following interruption in patients with multiple treatment failure. Aids 15:2189-2191.
8. Devereux HL, Youle M, Johnson MA, Loveday C. 1999. Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy. Aids 13:F123-F127.
9. Durant J, Clevenbergh P, Halfon P, Delgiudice P, Porsin S, Simonet P, Montagne N, Boucher CA, Schapiro JM, Dellamonica P. 1999. Drug-resistance genotyping in HIV-1 therapy: The VIRADAPT randomised controlled trial. Lancet 353:2195-2199.
10. Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK. 2002. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Ann Intern Med 137:381-433.
11. Fatkenheuer G, Theisen A, Rockstroh J, Grabow T, Wicke C, Becker K, Wieland U, Pfister H, Reiser M, Hegener P, Franzen C, Schwenk A, Salzberger B. 1997. Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients. Aids 11:F113-F116.
12. Hance AJ, Lemiale V, Izopet J, Lecossier D, Joly V, Massip P, Mammano F, Descamps D, Brun-Vezinet F, Clavel F. 2001. Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapy. J Virol 75:6410-6417.
13. Izopet J, Salama G, Pasquier C, Sandres K, Marchou B, Massip P, Puel J. 1998. Decay of HIV-1 DNA in patients receiving suppressive antiretroviral therapy. J Acquir Immune Defic Syndr Hum Retrovirol 19:478-483.
14. Izopet J, Massip P, Souyris C, Sandres K, Puissant B, Obadia M, Pasquier C, Bonnet E, Marchou B, Puel J. 2000. Shift in HIV resistance genotype after treatment interruption and short-term antiviral effect following a new salvage regimen. Aids 14:2247-2255.
15. Izopet J, Souyris C, Hance A, Sandres-Saune K, Alvarez M, Pasquier C, Clavel F, Puel J, Massip P. 2002a. Evolution of human immunodeficiency virus type 1 populations after resumption of therapy following treatment interruption and shift in resistance genotype. J Infect Dis 185:1506-1510.
16. Izopet J, Souyris C, Sandres-Saune K, Puissant B, Obadia M, Pasquier C, Puel J, Blancher A, Massip P. 2002b. Virological and immunological effects of salvage therapy following treatment interruption and a shift in HIV-1 resistance genotype. J Med Virol 68:305-310.
17. Katlama C, Dominguez S, Duvivier C. 2003. Long-term benefit of treatment interruption in salvage therapy (GIGHAART ANRS 097). 10th Conference on Retroviruses and Opportunistic Infections February 10-14.
18. Korber BT, Learn G, Mullins JI, Hahn BH, Wolinsky S. 1995. Protecting HIV databases. Nature 378:242-244.
19. Kwok S, Higuchi R. 1989. Avoiding false positives with PCR. Nature 339:237-238.
20. Lawrence J, Mayers DL, Hullsiek KH, Collins G, Abrams DI, Reisler RB, Crane LR, Schmetter BS, Dionne TJ, Saldanha JM, Jones MC, Baxter JD. 2003. Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus. N Engl J Med 349:837-846.
21. Ledergerber B, Egger M, Opravil M, Telenti A, Hirschel B, Battegay M, Vernazza P, Sudre P, Flepp M, Furrer H, Francioli P, Weber R. 1999. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study. Swiss HIV Cohort Study. Lancet 353:863-868.
22. Lucas GM, Chaisson RE, Moore RD. 1999. Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions. Ann Intern Med 131:81-87.
23. Meynard JL, Vray M, Morand-Joubert L, Race E, Descamps D, Peytavin G, Matheron S, Lamotte C, Guiramand S, Costagliola D, Brun-Vezinet F, Clavel F, Girard PM. 2002. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: A randomized trial. Aids 16:727-736.
24. Miller V, Sabin C, Hertogs K, Bloor S, Martinez-Picado J, D'Aquila R, Larder B, Lutz T, Gute P, Weidmann E, Rabenau H, Phillips A, Staszewski S. 2000. Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure. Aids 14:2857-2867.
25. Mussini C, Bugarini R, Perno CF, Antinori A, Borghi V, Bertoli A, D'Arrigo R, Bedini A, Mongiardo N, Cossarizza A, Esposito R. 2002. Kinetics of CD4 cells after discontinuation of antiretroviral therapy in patients with virological failure and a CD4 cell count greater than 500 cells/microl. Aids 16:1551-1554.
26. Ruiz L, Ribera E, Bonjoch A, Romeu J, Martinez-Picado J, Paredes R, Diaz M, Marfil S, Negredo E, Garcia-Prado J, Tural C, Sirera G, Clotet B. 2003. Role of structured treatment interruption before a 5-drug salvage antiretroviral regimen: The Retrogene Study. J Infect Dis 188:977-985.
27. Saitou N, Nei M. 1987. The neighbor-joining method: A new method for reconstructing phylogenetic trees. Mol Biol Evol 4:406-425.
28. Tural C, Ruiz L, Holtzer C, Schapiro J, Viciana P, Gonzalez J, Domingo P, Boucher C, Rey-Joly C, Clotet B. 2002. Clinical utility of HIV-1 genotyping and expert advice: The Havana trial. Aids 16:209-218.
29. Verhofstede C, Wanzeele FV, Van Der Gucht B, De Cabooter N, Plum J. 1999. Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype. Aids 13:2541-2546.
30. Wood E, Yip B, Hogg RS, Sherlock CH, Jahnke N, Harrigan RP, O'Shaughnessy MV, Montaner JS. 2000. Full suppression of viral load is needed to achieve an optimal CD4 cell count response among patients on triple drug antiretroviral therapy. Aids 14:1955-1960.
31. Yeni PG, Hammer SM, Carpenter CC, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schechter M, Schooley RT, Thompson MA, Vella S, Volberding PA. 2002. Antiretroviral treatment for adult HIV infection in 2002: Updated recommendations of the International AIDS Society-USA Panel. Jama 288:222-235.